IceCure Medical recently announced it received regulatory approval in China for its IceSense3 disposable cryoprobes.
With the approval, the company and its partners in China can begin to treat malignant and benign tissue of the breast, lung, bone, liver and kidneys, as well as palliative interventions.
“With approximately 430,000 new breast cancer cases in 2022 alone, and a healthcare system readily adopting new technologies that produce improved outcomes, we see China as a prime market for our cryoablation system,” CEO Eyal Shamir said in a news release. “Having received regulatory approval for commercial sales of both our console and cryoprobes, we expect to effectively monetize our distribution agreement in the Chinese market.”
IceSense3 is approved for use in combination with the company’s IceSense3 console. The system destroys tumors by freezing as an alternative to surgical tumor removal.
The company’s other cryoablation technology ProSense received FDA breakthrough device designation in 2021, and its cryogenic pump won a patent in Japan in January.
